Skip to main content

Table 2 Patient characteristics and perioperative data

From: Early reoperation following pancreaticoduodenectomy: impact on morbidity, mortality, and long-term survival

  Reoperation n = 48 No reoperation n = 385 P
Gender, m:f (ratio) 27:21 (1.28) 217:168 (1.29) 0.88
Age (years) 66.5 ± 11.4 64.6 ± 11.9 0.3
Comorbidities:
 HTN, n (%) 14 (29.1) 97 (25.1) 0.57
 IHD, n (%) 5 (10.4) 37 (9.6) 0.64
 DM, n (%) 9 (18.7) 118 (30.6) 0.19
 COPD, n (%) 1 (2) 2 (0.5) < 0.001
 Pre-op Hb 12.64 ± 1.5 12.27 ± 1.6 0.18
 CEA 3.73 ± 6.0 5.52 ± 14.8 0.54
 CA19-9 174 ± 289 209 ± 309 0.57
 Pre-op bilirubin 7.3 ± 6 4.19 ± 5.4 0.048
 Pre-op GGT 523 ± 497 458 ± 559 0.53
 Neo-adjuvant Tx, n (%) 2 (4.1) 12 (3.11) 0.14
 Benign pathology, n (%) 2 (4.1) 31 (8) 0.13
 Malignant pathology, n (%) 46 (95.9) 354 (91.9) 0.013
 PDAC, n (%) 28 (58.3) 198 (51.4) 0.98
 Ampullary CA, n (%) 6 (12.5) 47 (12.2) 0.814
 Duodenal CA, n (%) 1 (2) 15 (3.8) 0.014
 CCA, n (%) 5 (10.4) 15 (3.9) < 0.001
 ERCP + stenting (all malignant), n (%) 18 (39.1) 92 (25.9) 0.259
 ERCP + stenting (of CA, not CCA), n (%) 12 (34.2) 67 (25.5) 0.57
 ERCP + stenting (of CCA), n (%) 2 (40) 11 (73.3) 0.15
Staging of CA patients
 T1, n (%) 11 (27.5) 90 (32.4) 0.816
 T2, n (%) 13 (32.5) 108 (38.9) 0.85
 T3, n (%) 6 (15) 31 (11.2) 0.23
 T4, n (%) 10 (25) 48 (17.4) 0.2
 At least one positive LN, n (%) 20 (50) 140 (50.9) 0.87
 No. of positive LN, average (range) 2.3 (1–7) 3.2 (1–21) 0.19
 NET, n (%) 2 (4.16) 31 (8) 0.01
 IPMN, n (%) 1 (2) 40 (10.3) < 0.001
 Readmission, n (%) 11 (22.9) 66 (17.1) 0.24
 DGE, n (%) 3 (6.2) 57 (14.8) 0.002
 Wound infection, n (%) 4 (8.3) 63 (16.3) 0.019
 B/C pancreatic fistula, n (%) 7 (14.5) 57 (14.8) 0.93
 Tracheostomy, n (%) 7 (14.5) 2 (0.52) < 0.001
 LOS (days), average (range) 39.07 ± 30.15 16.5 ± 10.3 < 0.001
 60 days’ mortality, n (%) 9 (18.75) 10 (2.6) < 0.001
 Adjuvant Tx, n (% of CA patients) 23 (57.5) 181 (65.8) 0.58
  1. HTN hypertension, IHD ischemic heart disease, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, Ca carcinoma, CEA carcinoembryonic antigen, GGT gamma glutamyl transferase, Tx treatment, PDAC pancreatic adenocarcinoma, CCA cholangiocarcinoma, ERCP endoscopic retrograde cholangiopancreatography, LN lymph node, NET neuroendocrine tumor, IPMN intraductal papillary mucinous neoplasm, DGE delayed gastric emptying. LOS length of stay